Sign in

Bill Plovanek

Managing Director and Senior Equity Research Analyst at Canaccord Genuity

Bill Plovanic is a Managing Director and Senior Equity Research Analyst at Canaccord Genuity, specializing in U.S. medical technology coverage with a particular focus on companies such as Tandem Diabetes Care and TransMedics. Over his career, he has developed a track record for investment performance, achieving a success rate of approximately 49% and an average return of 5.82% per recommendation. Plovanic began his career in equity research over 20 years ago, has held senior analyst and leadership roles at First Albany Capital, and gained executive and board experience at Obalon Therapeutics before rejoining Canaccord Genuity in 2020. He holds a BS in finance from Bradley University, is a CFA charterholder, and maintains applicable professional securities credentials.

Bill Plovanek's questions to DEXCOM (DXCM) leadership

Question · Q3 2025

Bill Plovanek asked about the cadence of new patient starts during Q3, seeking insights into whether it was front- or back-end loaded to gauge Q4 confidence, and inquired about any trends in attrition rates amidst quality issues.

Answer

Jereme Sylvain, CFO, stated that attrition rates have been stable. Regarding new patient start cadence, he noted that while full September data isn't available, anecdotal evidence from sales leadership and the field suggests positive feedback as sensor deployment issues have waned, making them 'very encouraged' for Q4. Jake Leach, President and Interim CEO, added that prescribers confirm dramatic improvements in deployment issues.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts